Form 4: Adaptive Biotechnologies CFO Kyle Piskel Exercises Stock Options
SEC Form 4 Filing
Chief Financial Officer of Adaptive Biotechnologies, Kyle Piskel, exercised stock options on March 14, 2025, acquiring 2,500 shares of common stock.
Summary
- On March 14, 2025, Kyle Piskel, the Chief Financial Officer of Adaptive Biotechnologies, exercised stock options.
- This transaction resulted in the acquisition of 2,500 shares of common stock at a price of $6.32 per share.
- Following the transaction, Piskel directly owns 271,510 shares of Adaptive Biotechnologies common stock.
- The exercised stock options were fully vested and exercisable as of the transaction date.
Sentiment
Score: 5
Explanation: This is a neutral event. It's a standard Form 4 filing indicating a stock option exercise by the CFO. It doesn't inherently signal positive or negative sentiment.
Industry Context
Form 4 filings are standard practice and provide transparency into the transactions of company insiders, such as executives and directors. This allows investors to track changes in ownership and assess management's alignment with shareholder interests.
Stakeholder Impact
- The transaction has a minor impact on shareholders as it reflects an executive's compensation and confidence in the company.
Key Dates
| Date | Description |
|---|---|
| 03/14/2025 | Date of stock option exercise and acquisition of common stock. |
| 03/17/2025 | Date of signature on the Form 4 filing. |
| 11/08/2026 | Expiration date of the stock options. |
Disclaimer:The information provided here is for general informational purposes only and does not constitute financial advice, recommendation, or endorsement of any kind. It may contain errors or omissions. You should not rely on this information to make financial decisions. Always seek the advice of a qualified financial professional before making any investment or financial decisions. Use of this information is at your own risk.